Treatment with DAPs after the induction of depression in a mouse model can significantly reduce depression-like behaviors, lead to a significant reduction in neuronal damage, modulate the AMPK/Sirt1/NF-κB/NLRP3 pathway, and inhibit its mediated pyroptosis [54], thus indicating that DAPs are a candidate treatment for depression. This evidence concerns the gene SIRT1 and depressive symptom measurement.